DE2527636A1 - Verfahren zur herstellung von mycobakteriellen fraktionen - Google Patents
Verfahren zur herstellung von mycobakteriellen fraktionenInfo
- Publication number
- DE2527636A1 DE2527636A1 DE19752527636 DE2527636A DE2527636A1 DE 2527636 A1 DE2527636 A1 DE 2527636A1 DE 19752527636 DE19752527636 DE 19752527636 DE 2527636 A DE2527636 A DE 2527636A DE 2527636 A1 DE2527636 A1 DE 2527636A1
- Authority
- DE
- Germany
- Prior art keywords
- aqueous
- water
- mycobacterial
- cells
- suspension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 title description 4
- 210000004027 cell Anatomy 0.000 claims description 56
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 34
- 241001465754 Metazoa Species 0.000 claims description 30
- 239000000463 material Substances 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 239000000725 suspension Substances 0.000 claims description 23
- 239000003960 organic solvent Substances 0.000 claims description 21
- 241000187480 Mycobacterium smegmatis Species 0.000 claims description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- 239000000839 emulsion Substances 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 241000186363 Mycobacterium kansasii Species 0.000 claims description 11
- 239000012071 phase Substances 0.000 claims description 11
- 239000011343 solid material Substances 0.000 claims description 11
- 238000013019 agitation Methods 0.000 claims description 10
- 230000000259 anti-tumor effect Effects 0.000 claims description 8
- 239000007900 aqueous suspension Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000009385 viral infection Effects 0.000 claims description 8
- 208000036142 Viral infection Diseases 0.000 claims description 7
- 230000000840 anti-viral effect Effects 0.000 claims description 7
- 241000187481 Mycobacterium phlei Species 0.000 claims description 6
- 230000016507 interphase Effects 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 239000012074 organic phase Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000003223 protective agent Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 claims description 3
- 238000005063 solubilization Methods 0.000 claims description 3
- 230000007928 solubilization Effects 0.000 claims description 3
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000008346 aqueous phase Substances 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000000921 elemental analysis Methods 0.000 claims description 2
- 150000002337 glycosamines Chemical class 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 2
- 229940055036 mycobacterium phlei Drugs 0.000 claims 2
- 210000002421 cell wall Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001804 emulsifying effect Effects 0.000 claims 1
- 239000010410 layer Substances 0.000 claims 1
- 239000012044 organic layer Substances 0.000 claims 1
- 239000011368 organic material Substances 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 49
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 49
- 241000699670 Mus sp. Species 0.000 description 38
- 239000007924 injection Substances 0.000 description 17
- 238000002347 injection Methods 0.000 description 17
- 230000004083 survival effect Effects 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 229920001223 polyethylene glycol Polymers 0.000 description 12
- 231100000517 death Toxicity 0.000 description 11
- 230000034994 death Effects 0.000 description 11
- 108010058846 Ovalbumin Proteins 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 10
- 229940092253 ovalbumin Drugs 0.000 description 10
- 238000007912 intraperitoneal administration Methods 0.000 description 9
- 208000032839 leukemia Diseases 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 238000002513 implantation Methods 0.000 description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 8
- 229920000053 polysorbate 80 Polymers 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 206010003445 Ascites Diseases 0.000 description 7
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 208000003747 lymphoid leukemia Diseases 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 4
- 241000700198 Cavia Species 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000013459 approach Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000035931 haemagglutination Effects 0.000 description 3
- 229960001438 immunostimulant agent Drugs 0.000 description 3
- 239000003022 immunostimulating agent Substances 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229960001005 tuberculin Drugs 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000007093 Leukemia L1210 Diseases 0.000 description 2
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 239000002026 chloroform extract Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000035874 hyperreactivity Effects 0.000 description 2
- 230000002434 immunopotentiative effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- 206010006049 Bovine Tuberculosis Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000041183 Mycobacterium phlei DSM 43239 = CCUG 21000 Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- WPMWEFXCIYCJSA-UHFFFAOYSA-N Tetraethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCO WPMWEFXCIYCJSA-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- UYDLBVPAAFVANX-UHFFFAOYSA-N octylphenoxy polyethoxyethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCO)C=C1 UYDLBVPAAFVANX-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- -1 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000030279 prolonged fever Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/06—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using actinomycetales
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/32—Mycobacterium
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48145774A | 1974-06-20 | 1974-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2527636A1 true DE2527636A1 (de) | 1976-01-08 |
Family
ID=23912017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19752527636 Pending DE2527636A1 (de) | 1974-06-20 | 1975-06-20 | Verfahren zur herstellung von mycobakteriellen fraktionen |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JPS5132794A (enExample) |
| BE (1) | BE830486A (enExample) |
| DE (1) | DE2527636A1 (enExample) |
| FR (1) | FR2275224A1 (enExample) |
| GB (1) | GB1516507A (enExample) |
| NL (1) | NL7507376A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK153443B (da) * | 1977-08-09 | 1988-07-18 | Yuichi Yamamura | Fremgangsmaade til fremstilling af fast farmaceutisk praeparat indeholdende cellevaegsskelet fra nocardia rubra |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5428830A (en) * | 1977-08-09 | 1979-03-03 | Ichirou Azuma | Immunological treating agent of tumor containing glycolipid as effective component |
| JPS568320A (en) * | 1979-07-04 | 1981-01-28 | Chisato Maruyama | Drug for tumor immunotherapy comprising lipopolysaccharide as active constituent |
| CA1225592A (en) * | 1983-08-26 | 1987-08-18 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| IL71683A0 (en) * | 1984-04-27 | 1984-09-30 | Yeda Res & Dev | Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria |
| JP2522945B2 (ja) * | 1987-06-18 | 1996-08-07 | 呉羽化学工業株式会社 | 抗レトロウィルス剤 |
-
1975
- 1975-06-20 BE BE157548A patent/BE830486A/xx unknown
- 1975-06-20 GB GB26226/75A patent/GB1516507A/en not_active Expired
- 1975-06-20 DE DE19752527636 patent/DE2527636A1/de active Pending
- 1975-06-20 FR FR7519434A patent/FR2275224A1/fr active Granted
- 1975-06-20 JP JP50074550A patent/JPS5132794A/ja active Pending
- 1975-06-20 NL NL7507376A patent/NL7507376A/xx not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK153443B (da) * | 1977-08-09 | 1988-07-18 | Yuichi Yamamura | Fremgangsmaade til fremstilling af fast farmaceutisk praeparat indeholdende cellevaegsskelet fra nocardia rubra |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2275224B1 (enExample) | 1979-08-10 |
| NL7507376A (nl) | 1975-12-23 |
| BE830486A (fr) | 1975-12-22 |
| GB1516507A (en) | 1978-07-05 |
| FR2275224A1 (fr) | 1976-01-16 |
| JPS5132794A (en) | 1976-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3712768C2 (enExample) | ||
| DE3712767C2 (enExample) | ||
| DE69937343T2 (de) | Adjuvanszusammensetzung und methoden zu deren verwendung | |
| DE69524624T2 (de) | Saponinzubereitungen und deren verwendung in iscoms | |
| DE69826842T2 (de) | Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a | |
| DE3833319C2 (enExample) | ||
| DE60037514T2 (de) | Wässrige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a | |
| DE69724970T2 (de) | Verfahren zur behandlung von hypersensitivität typ i unter verwendung von monophosphoryl-lipid a | |
| DE69623072T3 (de) | Impfstoffzusammensetzung für Säugetiere enthaltend Squalen oder Squalan, Phospholipid und ein Tensid als Adjuvans | |
| AT408445B (de) | Neue attenuierte pseudomonas aeruginosa-stämme | |
| DE69605094T2 (de) | Quillajasaponin-zusatz und diesen enthaltende impfstoffformulierung | |
| DE2638762A1 (de) | Wasserloesliche adjuvantien, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
| CH640140A5 (de) | Verfahren zur herstellung von intravenoes injizierbarem gamma-globulin. | |
| DE2725204A1 (de) | Immunitaets-stimulierendes medikament und verfahren zu seiner herstellung | |
| DE69730434T2 (de) | Immunstimulierende lipidformulierung | |
| DE2603321A1 (de) | Emulsion auf der grundlage eines stoffwechselfaehigen pflanzlichen oels und wasser | |
| DE2325299A1 (de) | Aus mikroorganismen von der art der mycobakterien erhaltene, nicht-spezifische reizmittel, die eine antitumorimmunitaet hervorrufen und verfahren zu deren herstellung | |
| DE60019726T2 (de) | Impfstofformulierung mit monoglyceriden oder fettsäuren als adjuvans | |
| DE2547105A1 (de) | N-acetyl-muramyl-l-alanyl-d-isoglutamin enthaltende oelfreie adjuvanzien | |
| DE2527636A1 (de) | Verfahren zur herstellung von mycobakteriellen fraktionen | |
| DE3418820A1 (de) | Arzneimittel fuer verdauungsgeschwuer | |
| DE3516119A1 (de) | Polyvalentes hyperimmunglobulin-praeparat | |
| DE2823750C3 (de) | Verfahren zur Gewinnung mindestens eines Hydrolyseprodukts eines Endotoxins von Bordetella Pertussis | |
| DE2262427A1 (de) | Immunostimulierendes mittel und verfahren zu dessen herstellung | |
| DE2064296C2 (de) | Verfahren zur Herstellung eines injizierbaren Mittels gegen Viren der Mäuseleukämien |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHJ | Non-payment of the annual fee |